Drug reactions with skin manifestations. How to discover?
Abstract
Reasons of appearance and clinical manifestations of toxicodermia were considered. It was indicated that drug reactions with skin manifestations are extremely versatile. In some cases, the doctor cannot cancel the drug, and then the doctor should prescribe the treatment in order to mitigate the side effects of the drug, or find a substitute for this preparation. Regression in the eruptions after the preparation is cancelled also helps find the reason of the disease.
References
1. Gerogianni K., Tsezou A., Dimas K. Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention // Mol Diagn Ther. 2018, Jun; 22 (3): 297–314.
2. C. de la Torre, Oh H. J. Suh. Advances in the diagnosis of drug eruptions // Actas Dermosifiliogr. 2013, Nov; 104 (9): 782–788.
3. James W. D., Berger T. G., Elston D. M. Andrews Diseases of the Skin. Clinical Dermatology // Saunders Elsevier. 2006, 10 th edit.: 123.
4. Schneider J. A., Cohen P. R. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures // Adv Ther. 2017; 34 (6): 1235–1244.
5. Renn C. N., Straff W., Dorfm?ller A., Al-Masaoudi T., Merk H. F., Sachs B. Amoxicillin-induced Exanthema in Young Adults with Infectious Mononucleosis: Demonstration of Drug-specific Lymphocyte Reactivity // Br J Dermatol. 2002, Dec; 147 (6): 1166–1170.
6. Ramirez A., Perez-Perez L., Fernandez-Redondo V., Toribio J. Photoallergic Dermatitis Induced by Diltiazem // Contact Dermatitis. 2007: 56: 118–119.
7. Weyers W., Metze D. Histopathology of Drug Eruptions — General Criteria, Common Patterns, and Differential Diagnosis // Dermatol Pract Concept. 2011; 1 (1): 9: 33–47.
8. Ackerman A. B., Chongchitnant N., Sanchez J. et al. Histologic Diagnosis of Inflammatory Skin Diseases. 2 nd ed. Baltimore: Williams&Wilkins, 1997: 317.
9. Majdy N., Weyers W., Metze D. Histopathologic Features of Exanthematous Drug Eruptions of the Macular and Papular Type // Am J Dermatopathol. 2011; 33 (7): 695–704.
10. Busam K. J. Dermatopathology E-Book: A Volume in the Series: Foundations in Diagnostic Pathology (Expert Consult — Online), 2 nd ed, 2016. Elsevier/Saunders. Chapter 14. Hematopoetic Neoplasms: 603.
11. Goldberg I., Hanson M., Chodick G., Shirazi I., Brenner S. In Vitro Release of Interferon-Gamma from Peripheral Blood Lymphocytes in Cutaneous Adverse Drug Reactions // Clin Dev Immunol. 2012: 687532.
12. Barbaud A. Drug Patch Testing in Systemic Cutaneous Drug Allergy // Toxicology. 2005; 209 (2): 209–216.
13. Schulz J. T., Sheridan R. L., Ryan C. M., MacKool B., Tompkins R. G. A 10-Year Experience with Toxic Epidermal Necrolysis // J Burn Care Rehabil. 2000; 21 (3): 199–204.
14. Bastuji-Garin S., Fouchard N., Bertocchi M., Roujeau J. C., Revuz J., Wolkenstein P. SCORTEN: a Severity-of-illness Score for Toxic Epidermal Necrolysis // J. Invest. Dermatol. 2000; 115: 149–153.
15. Ruble J., Matsuo F. Anticonvulsant-Induced Cutaneous Reactions. Incidence, Mechanisms and Management // CNS Drugs. 1999, Sep; 12 (3): 215–236.
16. Walsh S. A., Creamer D. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a Clinical Update and Review of Current Thinking // Clinical and Experimental Dermatology. 36: 6–11.
17. Sheikh J. S., Farah S., Mohd A. Drug Reaction with Eosinophilia and Systemic Symptoms: Manifestations, Treatment, and Outcome in 17 Patients // Int J Dermatol. 2015, 54: 537–542.
18. Shiohara T., Inaoka M., Kano Y. Drug-induced Hypersensitivity Syndrome (DIHS): A Reaction Induced by a Complex Interplay among Herpesviruses and Antiviral and Antidrug Immune Responses // Allergol. Int. 2006; 55: 1–8.
19. Koumantaki-Mathioudaki E., Papadavid E., Katsambas A. Generalized pustular drug eruptions // JADV. 1999, 12: 196–197.
20. Ardeshna K. P., Rohatgi S., Jerajani H. R. Fixed Drug Eruption to Cetirizine: An Unusual Villain // Indian Dermatol Online J. 2018, Jan-Feb; 9 (1): 55–57.
21. Mi-Yeong K., Eun-Jung J., Yoon-Seok C., Sang-Heon C., Kyung-Up M., Sae-Hoon K. A Case of Levocetirizine-induced Fixed Drug Eruption and Cross-reaction with Piperazine Derivatives // Asia Pac Allergy. 2013, Oct; 3 (4): 281–284.
22. Drucker A. M., Rosen C. F. Drug-Induced Photosensitivity. Culprit Drugs, Management and Prevention // Drug Safety. 2011; 34 (10): 821–837.
23. Sehgal V. N., Jain S., Bhattacharya S. N. Cutaneous drug reactions // JEADV. 1993, 2: 281–295.
24. Frigas E., Nzeako U. C. Angioedema. Pathogenesis, differential diagnosis, and treatment // Clin Rev Allergy Immunol. 2002; 23 (2): 217–231.
25. Lasser E. C. Chasing Contrast Molecules: A 45 Year Quixotic Quest // Acad Radiol. 2004; 11: 1190–1196.
26. Bush W. H., Segal A. J. Recognition and Treatment of Acute Contrast Reactions // Appl Radiol December. 2009: 21,16–21.
27. Brenner S., Bialy-Golan A., Ruocco V. Drug-induced Pemphigus // Clin Dermatol. 1998; 6 (3): 393–397.
28. Халиулин Ю. Г., Урбанский А. С. Современные подходы к диагностике и медикаментозной терапии дерматозов. Учебное пособие для системы послевузовского и дополнительного профессионального образования врачей. Кемерово: КемГМА, 2011. 165 с.
29. Valeyrie-Allanore L., Sassolas B., Roujeau J.-C. Drug-Induced Skin, Nail and Hair Disorders // Drug Safety. 2007; 30 (11): 1011–1030.
30. Virendra N. S., Sanjiv J., Sambit N. B. Cutaneous drug reactions // JEADV. 1993, 2: 281–295.
31. Femiano F., Lanza A., Buonaiuto C. et al. Oral Manifestations of Adverse Drug Reactions: Guidelines // JEADV. 2008, 22: 681–691.
32. Tack D. A., Rogers R. S. Oral Drug Reactions // Dermatologic Therapy 2002, 15: 236–250.
33. Moore D. E. Drug-Induced Cutaneous Photosensitivity. Incidence, Mechanism, Prevention and Management // Drug Safety. 2002; 25 (5), p. 356.
Review
For citations:
Haliulin Yu.G., Macharadze D.Sh. Drug reactions with skin manifestations. How to discover? Lechaschi Vrach. 2018;(11):79. (In Russ.)
Views:
165
JATS XML
Email this article 
